lirilumab

Home
Ligands
lirilumab

GtoPdb Ligand ID: 9310

Synonyms: 1-7F9 | BMS-986015 | IPH2102

Comment: Lirilumab (BMS-986015) is a fully human monoclonal antibody (mAb) which targets the KIRD2 subgroup of killer cell immunoglobulin like receptors (KIRs) on natural killer cells [1], being developed as an immuno-oncology clinical candidate. Identified targets include KIR2DL1, KIR2DL2, KIR2DL3, KIR2DS1 and KIR2DS2. Genes of KIR proteins are listed in HGNC family Killer cell immunoglobulin like receptors (KIR). ia an IgG4 isotype antibody considered suitable for a blocking , non-depleting mAb with clinical utility.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Bioactivity Comments
Avidities of 1-7F9 (lirilumab) for KIR2DL1 and KIR2DL3 are 0.43 and 0.025nM respectively, assessed by Biacore analysis [1]. In preclinical functional studies 1-7F9 provides stable blockade of KIR inhibitory signals and boosts NK-mediated killing in vitro and in vivo [1]

Bioactivity Comments

Avidities of 1-7F9 (lirilumab) for KIR2DL1 and KIR2DL3 are 0.43 and 0.025nM respectively, assessed by Biacore analysis [1]. In preclinical functional studies 1-7F9 provides stable blockade of KIR inhibitory signals and boosts NK-mediated killing in vitro and in vivo [1]